Dry AMD and Geographic Atrophy
Diagnosing and Managing the
dry AMD and GA Patient
Diagnosing and Monitoring GA in
Today’s Practice
Practical Considerations
for GA Treatment
Demographics and Diagnosis
Disease Progression & Monitoring
Disease Management
Emerging Treatments
Podcasts
Part 1
Demographics and Diagnosis
In this episode of the EURETINA IME expert consensus podcast series on dry AMD and GA Profs. Peter Kaiser, Stela Vujosevic and Patricia Udaondo discuss dry AMD patient demographics and risk factors as well as best practices for early diagnosis. Make sure to listen to the other podcasts in this series. Independent medical education supported by Apellis, Iveric Bio (an Astellas Company) and Zeiss.
Podcasts
Part 2
Disease Progression and Monitoring
In this episode of the EURETINA IME expert consensus podcast series on dry AMD and GA Profs. Peter Kaiser, Stela Vujosevic and Patricia Udaondo discuss key consideration to identify biomarkers for disease progression and monitoring of GA patients. Make sure to listen to the other podcasts in this series. Independent medical education supported by Apellis, Iveric Bio (an Astellas Company) and Zeiss.
Podcasts
Part 3
Disease Management
In this episode of the EURETINA IME expert consensus podcast series on dry AMD and GA Profs. Peter Kaiser, Stela Vujosevic and Patricia Udaondo discuss best practices for managing dry AMD and GA patients in today’s practice. Make sure to listen to the other podcasts in this series. Independent medical education supported by Apellis, Iveric Bio (an Astellas Company) and Zeiss.
Podcasts
Part 4
Emerging Treatments
In this episode of the EURETINA IME expert consensus podcast series on dry AMD and GA Profs. Peter Kaiser, Stela Vujosevic and Patricia Udaondo discuss emerging treatment options and how to talk to patients about these upcoming therapies. Make sure to listen to the other podcasts in this series. Independent medical education supported by Apellis, Iveric Bio (an Astellas Company) and Zeiss.
In this IME eLearning module Prof Sandrine Zweifel (University Hospital Zurich, Switzerland) outlines the updated CAM group staging classification for AMD, and how it supports monitoring of the disease anatomically and functionally. She will also touch on the benefits this will have on future clinical trials and in treating patients.
In this IME eLearning module Eleonora Lad (Duke University Medical Center, Durham, NC, USA) and Veeral Sheth (University Retina, Chicago, IL, USA) will look at how the complement cascade causes damage, why C3 and C5 inhibition therapies have been developed, and the evidence as shown from clinical trials that blocking these complement factors will slow down the progression of geographic atrophy.
Apellis – Iveric Bio (an Astellas Company) – Zeiss